AbbVie Looking to Raise $28 Billion in High-Grade Bond Market

AbbVie plans to raise $28 billion in the bond market to finance its $63 billion acquisition of Allergan. This would be the fourth largest US corporate bond offering. The current market conditions are favorable for such financing, with investment grade bond yields at their narrowest spread since 2018. The bond is rated Triple B, a sector that has grown rapidly and raised some concerns, though it has performed well recently.

What concerns are raised regarding the Triple B rated tier?

When is AbbVie expected to come to the market with their bond offering?